BlackRock Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

BlackRock Group’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14,143	Closed	-$21K	–	3116
2016 Q1	$21K	Buy	14,143 +9,329	+194%	+$18.4K	﹤0.01%	3026
2015 Q4	$15K	Hold	4,814	–	–	﹤0.01%	2975
2015 Q3	$30K	Buy	+4,814	New	+$45K	﹤0.01%	2930
2014 Q3	–	Sell	-5,943	Closed	-$40K	–	2957
2014 Q2	$40K	Sell	5,943 -81,914	-93%	-$521K	﹤0.01%	2723
2014 Q1	$636K	Buy	+87,857	New	+$521K	﹤0.01%	2159

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock Group's NWBO Position: Q2 2016 in Review

BlackRock Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 14,143 shares — an estimated $21K sold.

BlackRock Group first reported a position in NWBO in Q1 2014 and held it in 5 quarters. The position peaked at $636K in Q1 2014. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

BlackRock Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
BlackRock Group sold 14,143 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $21K.
BlackRock Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 5 quarters.
BlackRock Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $636K in Q1 2014.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on BlackRock Group's 13F filing for Q2 2016, filed 10 Aug 2016.